242 related articles for article (PubMed ID: 17602978)
21. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
Johnson G; Carson P; Francis GS; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
[TBL] [Abstract][Full Text] [Related]
22. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
[TBL] [Abstract][Full Text] [Related]
23. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN;
N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851
[TBL] [Abstract][Full Text] [Related]
24. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Zamani P; Akers S; Soto-Calderon H; Beraun M; Koppula MR; Varakantam S; Rawat D; Shiva-Kumar P; Haines PG; Chittams J; Townsend RR; Witschey WR; Segers P; Chirinos JA
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28219917
[TBL] [Abstract][Full Text] [Related]
25. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
Ziaeian B; Fonarow GC; Heidenreich PA
JACC Heart Fail; 2017 Sep; 5(9):632-639. PubMed ID: 28711446
[TBL] [Abstract][Full Text] [Related]
26. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
[TBL] [Abstract][Full Text] [Related]
27. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Cohn JN
Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
[TBL] [Abstract][Full Text] [Related]
28. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
[TBL] [Abstract][Full Text] [Related]
29. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
[TBL] [Abstract][Full Text] [Related]
30. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
31. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
Carmody MS; Anderson JR
Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
[TBL] [Abstract][Full Text] [Related]
32. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
Golwala HB; Thadani U; Liang L; Stavrakis S; Butler J; Yancy CW; Bhatt DL; Hernandez AF; Fonarow GC
J Am Heart Assoc; 2013 Aug; 2(4):e000214. PubMed ID: 23966379
[TBL] [Abstract][Full Text] [Related]
33. Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.
Chang KW; Beri N; Nguyen NH; Arbit B; Fox S; Mojaver S; Clopton P; Tam SW; Taylor AL; Cohn JN; Maisel AS; Anand IS
J Card Fail; 2018 May; 24(5):303-309. PubMed ID: 28918108
[TBL] [Abstract][Full Text] [Related]
34. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT).
Wiggers H; Køber L; Gislason G; Schou M; Poulsen MK; Vraa S; Nielsen OW; Bruun NE; Nørrelund H; Hollingdal M; Barasa A; Bøttcher M; Dodt K; Hansen VB; Nielsen G; Knudsen AS; Lomholdt J; Mikkelsen KV; Jonczy B; Brønnum-Schou J; Poenaru MP; Abdulla J; Raymond I; Mahboubi K; Sillesen K; Serup-Hansen K; Madsen JS; Kristensen SL; Larsen AH; Bøtker HE; Torp-Petersen C; Eiskjær H; Møller J; Hassager C; Steffensen FH; Bibby BM; Refsgaard J; Høfsten DE; Mellemkjær S; Gustafsson F
Am Heart J; 2021 Jan; 231():137-146. PubMed ID: 33039340
[TBL] [Abstract][Full Text] [Related]
35. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Franciosa JA; Taylor AL; Cohn JN; Yancy CW; Ziesche S; Olukotun A; Ofili E; Ferdinand K; Loscalzo J; Worcel M;
J Card Fail; 2002 Jun; 8(3):128-35. PubMed ID: 12140804
[TBL] [Abstract][Full Text] [Related]
36. Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
Nyolczas N; Dékány M; Muk B; Szabó B
Adv Exp Med Biol; 2018; 1067():31-45. PubMed ID: 29086392
[TBL] [Abstract][Full Text] [Related]
37. Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Ghali JK; Tam SW; Sabolinski ML; Taylor AL; Lindenfeld J; Cohn JN; Worcel M
J Card Fail; 2008 Nov; 14(9):718-23. PubMed ID: 18995175
[TBL] [Abstract][Full Text] [Related]
38. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group.
Wong M; Johnson G; Shabetai R; Hughes V; Bhat G; Lopez B; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI65-70. PubMed ID: 8500242
[TBL] [Abstract][Full Text] [Related]
39. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
McNamara DM; Tam SW; Sabolinski ML; Tobelmann P; Janosko K; Venkitachalam L; Ofili E; Yancy C; Feldman AM; Ghali JK; Taylor AL; Cohn JN; Worcel M
J Card Fail; 2009 Apr; 15(3):191-8. PubMed ID: 19327620
[TBL] [Abstract][Full Text] [Related]
40. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
Fletcher RD; Cintron GB; Johnson G; Orndorff J; Carson P; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI49-55. PubMed ID: 8500239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
